Rituximab in the treatment of inflammatory myopathies: a review

被引：83
|
作者：
Fasano, Serena [1 ]
Gordon, Patrick [2 ]
Hajji, Raouf [3 ]
Loyo, Esthela [4 ]
Isenberg, David A. [5 ]
机构：
[1] Univ Naples 2, Dept Clin & Expt Med, Rheumatol Unit, Naples, Italy
[2] Kings Coll Hosp London, Ctr Rheumatol, Dept Med, London, England
[3] Sidi Bouzid Hosp, Fac Sousse, Dept Internal Med, Ibn Aljazzar Med, Sidi Bouzid, Tunisia
[4] Serv Reumatol Inmunol Clin HRUJMCB, Jefe Serv, Santiago, Dominican Rep
[5] UCL, Dept Med, Ctr Rheumatol, London, England
来源：
RHEUMATOLOGY | 2017年 / 56卷 / 01期
关键词：
inflammatory myopathies; dermatomyositis; polymyositis; anti-synthetase syndrome; rituximab; INTERSTITIAL LUNG-DISEASE; ANTI-SYNTHETASE SYNDROME; CELL DEPLETION THERAPY; JUVENILE DERMATOMYOSITIS; REFRACTORY POLYMYOSITIS; RESPIRATORY-FAILURE; MYOSITIS; EFFICACY; PATIENT; ADULT;
D O I：
10.1093/rheumatology/kew146
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Several uncontrolled studies have encouraged the use of rituximab (RTX) in patients with myositis. Unfortunately, the first placebo-phase trial to assess the efficacy of RTX in refractory myositis did not show a significant difference between the two treatment groups, and doubts have been expressed about its study design. In this review we present an up-to-date overview of the reported experiences of RTX therapy in myositis. A PubMed search was performed to find all the available cases of refractory myositis patients treated with RTX up to July 2015. The following terms were assessed: inflammatory myopathies OR anti-synthetase syndrome OR polymyositis OR dermatomyositis AND RTX. A total of 48 studies were included. We identified 458 patients with myositis treated with RTX. We found a rate of response to RTX of 78.3%. RTX can play a role in the management of patients with myositis, at least in those with positive myositis-specific autoantibodies.
引用
收藏
页码：26 / 36
页数：11
相关论文
共 50 条
  • [1] Rituximab treatment in patients with refractory inflammatory myopathies
    Mahler, Elien A. M.
    Blom, Marlies
    Voermans, Nicol C.
    van Engelen, Baziel G. M.
    van Riel, Piet L. C. M.
    Vonk, Madelon C.
    RHEUMATOLOGY, 2011, 50 (12) : 2206 - 2213
  • [2] Successful treatment with rituximab in patients with refractory inflammatory myopathies
    Blom, M.
    Van den Hoogen, F. H. J.
    Voermans, N. C.
    Van Riel, P. L. C. M.
    Preijers, F. W. M. B.
    Van Engelen, B. G. M.
    Barrera, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 202 - 202
  • [3] Rituximab, alternative treatment in refractory idiopathic inflammatory myopathies
    Aranda-Pereira, P.
    Melendez-Mercado, C.
    Jaimes-Hernandez, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 199 - 199
  • [4] Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature
    Rios Fernandez, R.
    Callejas Rubio, J. -L.
    Sanchez Cano, D.
    Saez Moreno, J. -A.
    Ortego Centeno, N.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (06) : 1009 - 1016
  • [5] Rituximab in inflammatory myopathies: "A neolithic revolution"
    Hervier, B.
    Benveniste, O.
    REVUE DE MEDECINE INTERNE, 2015, 36 (08): : 505 - 508
  • [6] Rituximab for Inflammatory Myopathies in a Colombian Cohort
    Santos, Victor A.
    Aragon, Cristian C.
    Posso-Osorio, Ivan
    Naranjo-Escobar, Juan
    Milisenda, J. C.
    Obando, Maria Alejandra
    Barrera, Tatiana
    Zamorano, Laura
    Hormaza-Jaramillo, Andres
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S232 - S235
  • [7] Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis
    Zhen, Chao
    Hou, Ying
    Zhao, Bing
    Ma, Xiaotian
    Dai, Tingjun
    Yan, Chuanzhu
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [8] The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature
    Barsotti, S.
    Cioffi, E.
    Tripoli, A.
    Tavoni, A.
    d'Ascanio, A.
    Mosca, M.
    Neri, R.
    REUMATISMO, 2018, 70 (02) : 78 - 84
  • [9] RITUXIMAB IN INFLAMMATORY MYOPATHIES: A SINGLE CENTER EXPERIENCE
    Costi, A. C.
    Pena, C.
    Aguila Maldonado, R.
    Pera, M. A.
    Garcia, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1664 - 1665
  • [10] Responsiveness of rituximab in refractory cases of inflammatory myopathies
    No, J.
    Park, Y.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S96 - S96
12345